News
Displaying 201–210 of 536
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Foundation News
This December 16th exclusive in-person performance and conversation with the Blind Boys of Alabama will raise awareness for blinding diseases.
-
In the Press
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
-
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Foundation NewsPatient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Opus Genetics Announces Two Key Leadership Appointments
In the PressDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Foundation Fighting Blindness Appoints Richele Donat, SPHR, as Chief Human Resources Officer
Foundation NewsMs. Donat brings over twenty years of successful human resource leadership experience to the Foundation executive team
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Covid Revealed What Science Can Do When Funding is Found
In the Press‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
.png)
.png)
